Connect your AI

Haemonetics HAE Stock-Based Comp

Stock-Based Comp at other companies

AbbottABT

$317M+9.7%

TFX

TeleflexTFX

$6.74M+1.7%

Boston ScientificBSX

$83M+12.2%

MedtronicMDT

$95M+6.7%

LivaNovaLIVN

$8.27M+6.3%

ICU MedicalICUI

$14.01M+15.0%

Other financials

Income statement

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

Market cap$3.31B-18.0%

Profitability

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Haemonetics's stock-based comp?: Haemonetics (HAE) reported stock-based comp of $9.13M in Q1 2026.
How has Haemonetics's stock-based comp changed year-over-year?: Haemonetics's stock-based comp increased by 31.6% year-over-year, from $6.94M to $9.13M.
What is the long-term trend for Haemonetics's stock-based comp?: Over 4 years (2022 to 2026), Haemonetics's stock-based comp has grown at a 8.6% compound annual growth rate (CAGR), from $24.36M to $33.83M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.